Investors
Information Disclosure
-
VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO RESTRICTED SHARE AWARD SCHEME2022.04.22
-
VOLUNTARY ANNOUNCEMENT - ENTERING INTO THE COOPERATIVE AGREEMENT IN RELATION TO COMBINATION THERAPIES2022.04.21
-
VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO RESTRICTED SHARE AWARD SCHEME2022.04.21
-
VOLUNTARY ANNOUNCEMENT - CATEGORY I ANTI-TUMOR INNOVATIVE DRUG "TQB2930" OBTAINED APPROVAL FOR CLINICAL TRIAL2022.04.20
-
VOLUNTARY ANNOUNCEMENT - “ANLOTINIB HYDROCHLORIDE CAPSULES” OBTAINED APPROVAL FOR THE FIFTH INDICATION2022.04.19
-
VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO RESTRICTED SHARE AWARD SCHEME2022.04.14
-
NEXT DAY DISCLOSURE RETURN2022.04.11
-
VOLUNTARY ANNOUNCEMENT INNOVATIVE DRUG "TQ-B3525" WAS INCLUDED IN THE LIST OF BREAKTHROUGH THERAPY DRUGS BY CDE2022.04.08